China is a nation primed for clinical trial development and early market access, especially for emerging biopharma (EBPs). With a population of more than 1.4 billion and currently standing as the world's second-largest biopharmaceutical market, China brings great potential and benefits for EBPs that are launching niche and novel therapies. Featuring a wide array of growth opportunities, EBPs can leverage on China's huge market potential, faster approval pathways and National Reimbursement Drug List (NRDL) access, new R&D and commercialization options as well as extensive capital and experienced professionals.

Globally, the COVID-19 pandemic has created challenges and risks for companies to conduct their clinical research and trials. To enable a smooth first-launch process and market entry success in China, it is vital for EBPs to consider the right clinical trial development and market entry strategy, whether partnership with a big pharma, distributor, alone, or global commercial solutions provider. Download our whitepaper to learn more about the China opportunity for EBPs in navigating development and product launches in a rapid, flexible and seamless manner.